Abstract
Tuberous sclerosis complex (TSC) affects approximately one to two million people worldwide. Nowadays renal lesions are the leading cause of death in Angiomyolipoma (AML) related to tuberous sclerosis. The new role of Everolimus (mTOR Inhibitor) has come in patients of Large AML with TSC in the last decade.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
